MX2010005243A - Composiciones corticosteroides. - Google Patents
Composiciones corticosteroides.Info
- Publication number
- MX2010005243A MX2010005243A MX2010005243A MX2010005243A MX2010005243A MX 2010005243 A MX2010005243 A MX 2010005243A MX 2010005243 A MX2010005243 A MX 2010005243A MX 2010005243 A MX2010005243 A MX 2010005243A MX 2010005243 A MX2010005243 A MX 2010005243A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- corticosteroid compositions
- corticosteroid
- compositions
- esophagus
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 210000003238 esophagus Anatomy 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Se proporcionan en la presente métodos para tratar, prevenir o aliviar los síntomas de inflamación asociados con enfermedades inflamatorias y afecciones del tracto gastrointestinal, por ejemplo, aquellas que involucran el esófago. También se proporcionan en la presente composiciones farmacéuticas útiles para los métodos de la presente invención.
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98772007P | 2007-11-13 | 2007-11-13 | |
US1201207P | 2007-12-06 | 2007-12-06 | |
US1599807P | 2007-12-21 | 2007-12-21 | |
US1981808P | 2008-01-08 | 2008-01-08 | |
US3494108P | 2008-03-07 | 2008-03-07 | |
US3534808P | 2008-03-10 | 2008-03-10 | |
US5410708P | 2008-05-16 | 2008-05-16 | |
US5410608P | 2008-05-16 | 2008-05-16 | |
US5410408P | 2008-05-16 | 2008-05-16 | |
US5410508P | 2008-05-16 | 2008-05-16 | |
US5410308P | 2008-05-16 | 2008-05-16 | |
US9056808P | 2008-08-20 | 2008-08-20 | |
PCT/US2008/012780 WO2009064457A2 (en) | 2007-11-13 | 2008-11-12 | Corticosteroid compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2010005243A true MX2010005243A (es) | 2010-08-23 |
MX349677B MX349677B (es) | 2017-08-08 |
Family
ID=40639386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010005243A MX349677B (es) | 2007-11-13 | 2008-11-12 | Composiciones corticosteroides. |
Country Status (23)
Country | Link |
---|---|
US (5) | US20090149433A1 (es) |
EP (7) | EP2214679B1 (es) |
JP (6) | JP2011503113A (es) |
KR (1) | KR101245604B1 (es) |
AU (3) | AU2008321396A1 (es) |
CA (5) | CA2705681C (es) |
CY (2) | CY1120048T1 (es) |
DK (4) | DK2214677T3 (es) |
ES (5) | ES2644496T3 (es) |
GB (1) | GB2458403B (es) |
HK (1) | HK1256861A1 (es) |
HR (2) | HRP20180408T1 (es) |
HU (1) | HUE038452T2 (es) |
IL (5) | IL205548A0 (es) |
LT (2) | LT3354276T (es) |
MX (1) | MX349677B (es) |
NZ (1) | NZ585268A (es) |
PL (3) | PL2214679T3 (es) |
PT (4) | PT3354276T (es) |
RU (1) | RU2491074C2 (es) |
SI (2) | SI2211896T1 (es) |
WO (5) | WO2009064457A2 (es) |
ZA (1) | ZA201003358B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
EP1802285B1 (en) | 2004-10-21 | 2013-02-27 | Aptalis Pharmatech, Inc. | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
US20090123551A1 (en) * | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Gastrointestinal delivery systems |
GB2458403B (en) | 2007-11-13 | 2010-01-13 | Meritage Pharma Inc | Stabilised corticosteroid compositions |
US9050368B2 (en) * | 2007-11-13 | 2015-06-09 | Meritage Pharma, Inc. | Corticosteroid compositions |
US20090264392A1 (en) * | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
JP5709266B2 (ja) * | 2008-12-08 | 2015-04-30 | ソリジェニックス、インコーポレイテッド | 放射線及び化学療法傷害に用いる局所的に活性なステロイド |
EP2440210A4 (en) * | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
CN106421797A (zh) * | 2009-10-01 | 2017-02-22 | 艾戴尔医药公司 | 口服给予的皮质类固醇组合物 |
JP2013515490A (ja) * | 2009-12-23 | 2013-05-09 | ヴァックスジーン コーポレーション | 組み換え型乳酸連鎖球菌のミニカプセルの経口投与による免疫保護 |
US9119887B2 (en) | 2010-09-16 | 2015-09-01 | Mo-Sci Corporation | Low-density magnesium-aluminum-silicate (MAS) microparticles for radiotherapy and/or radioimaging |
US8865123B1 (en) | 2010-09-16 | 2014-10-21 | Mo-Sci Corporation | Strontium phosphate microparticle for radiological imaging and therapy |
US9849200B2 (en) | 2010-09-16 | 2017-12-26 | Mo-Sci Corporation | Strontium phosphate microparticle for radiological imaging and therapy |
WO2013055251A1 (ru) * | 2011-10-14 | 2013-04-18 | Общество С Ограниченной Ответственностью "Цитонир" | Пероральная фармацевтическая композиция для лечения воспалительных заболеваний желудочно-кишечного тракта |
JP5456802B2 (ja) * | 2012-01-23 | 2014-04-02 | 株式会社Cac | 細胞遊走促進剤及び創傷治療用の経皮吸収剤 |
BR112014027681B8 (pt) | 2012-05-08 | 2023-10-31 | Aciex Therapeutics Inc | Nanocristais de propionato de fluticasona, composição tópica farmacêutica compreendendo os mesmos, seu uso e método de fabricação |
EP3181120A1 (en) * | 2012-11-09 | 2017-06-21 | Scidose LLC | Enema composition for treatment of ulcerative colitis having long term stability |
WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
FI2886108T4 (fi) | 2013-12-23 | 2023-02-22 | Optimoitu farmaseuttinen koostumus ruokatorven tulehduksellisten muutosten hoitoon | |
EP2886121A1 (de) | 2013-12-23 | 2015-06-24 | Dr. Falk Pharma Gmbh | Wässrige Suspension enthaltend Budesonid zur Behandlung von entzündlichen Veränderungen des Ösophagus |
EP3047846A1 (en) * | 2015-01-22 | 2016-07-27 | Ems S.A. | Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus |
WO2016205172A1 (en) | 2015-06-15 | 2016-12-22 | Banner Life Sciences Llc | Soft lozenges comprising corticosteroids |
US9867834B2 (en) | 2015-06-15 | 2018-01-16 | Banner Life Sciences Llc | Non-systemic topical compositions comprising corticosteroids |
EP3435982A1 (en) | 2016-03-31 | 2019-02-06 | VHsquared Limited | Compositions |
GB201608276D0 (en) * | 2016-05-11 | 2016-06-22 | Abbott Lab | Additive for a nutritional composition |
TWI728172B (zh) * | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
ES2977556T3 (es) * | 2016-08-31 | 2024-08-26 | Lilly Co Eli | Pauta posológica para el tratamiento de tumores sólidos |
US10612929B2 (en) * | 2017-10-17 | 2020-04-07 | AI Incorporated | Discovering and plotting the boundary of an enclosure |
SG11202008144UA (en) * | 2018-02-28 | 2020-09-29 | Baylor College Medicine | Proton pump inhibitors and methods of use in chemoradiation-induced tissue inflammation and scarring |
WO2020011938A1 (en) * | 2018-07-11 | 2020-01-16 | Medizinische Universität Wien | Glucocorticoids for the topical treatment of autoimmune gastritis |
CN113271979A (zh) * | 2018-10-24 | 2021-08-17 | 费灵有限公司 | 皮质类固醇的粘膜粘附性药物组合物 |
US20220133818A1 (en) * | 2019-02-26 | 2022-05-05 | The Regents Of The University Of Colorado, A Body Corporate | Method and composition for treating gastrointestinal inflammatory disorders |
WO2020254826A1 (en) | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
CA3144567A1 (en) | 2019-06-21 | 2020-12-24 | Scott Crowe | Polypeptides |
US20210330900A1 (en) * | 2020-04-22 | 2021-10-28 | Topical Sinus Therapeutics, Inc. | TARGETED ADMINISTRATION TO THE OROPHARYNX OF VISCOUS OR DRY POWDER FLUTICASONE PROPIONATE AND RELATED CORTICOSTEROIDS FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EoE) |
US11904046B1 (en) * | 2022-11-14 | 2024-02-20 | Eton Pharmaceuticals, Inc. | Hydrocortisone oral liquid formulations |
Family Cites Families (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2861920A (en) | 1954-05-04 | 1958-11-25 | Upjohn Co | Therapeutic suspensions of steroids containing pvp and/or pva |
US3539365A (en) | 1967-02-13 | 1970-11-10 | Fmc Corp | Dispersing and stabilizing agent comprising beta-1,4 glucan and cmc and method for its preparation |
US4361545A (en) | 1979-05-21 | 1982-11-30 | Rowell Laboratories, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion |
JPS5762284A (en) | 1980-10-01 | 1982-04-15 | Sumitomo Chem Co Ltd | Stabilizing method |
US4440763A (en) | 1981-03-18 | 1984-04-03 | Block Drug Company, Inc. | Use of 4-aminosalicyclic acid as an anti-inflammatory agent |
US4372861A (en) * | 1981-05-04 | 1983-02-08 | Atlantic Richfield Company | Graphite dispersion |
US4427681A (en) | 1982-09-16 | 1984-01-24 | Richardson-Vicks, Inc. | Thixotropic compositions easily convertible to pourable liquids |
US4539198A (en) | 1983-07-07 | 1985-09-03 | Rowell Laboratories, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range |
US4684534A (en) | 1985-02-19 | 1987-08-04 | Dynagram Corporation Of America | Quick-liquifying, chewable tablet |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
GB8628359D0 (en) | 1986-11-27 | 1986-12-31 | Zyma Sa | Galenical formulation |
GB8630913D0 (en) | 1986-12-24 | 1987-02-04 | Glaxo Group Ltd | Pharmaceutical compositions |
US5446070A (en) | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US4900552A (en) | 1988-03-30 | 1990-02-13 | Watson Laboratories, Inc. | Mucoadhesive buccal dosage forms |
CA1340994C (en) | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
US5643602A (en) | 1989-11-22 | 1997-07-01 | Astra Aktiebolag | Oral composition for the treatment of inflammatory bowel disease |
JPH04312526A (ja) | 1991-04-09 | 1992-11-04 | Fujisawa Pharmaceut Co Ltd | 骨疾患治療剤 |
EP0516345A1 (en) * | 1991-05-28 | 1992-12-02 | Eli Lilly And Company | Use of nizatidine for the manufacture of a medicament for the treatment of reflux esophagitis |
US5380535A (en) | 1991-05-28 | 1995-01-10 | Geyer; Robert P. | Chewable drug-delivery compositions and methods for preparing the same |
CA2131285C (en) | 1992-03-10 | 2004-06-29 | Lewis James Baskeyfield | Pharmaceutical inhalation compositions |
JPH06107550A (ja) | 1992-09-29 | 1994-04-19 | Yutaka Kurachi | 経口抗炎症剤 |
PE44995A1 (es) | 1994-01-27 | 1995-12-18 | Schering Corp | Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias |
TW438601B (en) * | 1994-05-18 | 2001-06-07 | Janssen Pharmaceutica Nv | New mucoadhesive emulsion compositions and a process for the preparation thereof |
GB9505032D0 (en) * | 1995-03-13 | 1995-05-03 | Westminster Lab Ltd | Improvements in or relating to organic compositions |
WO1996009829A1 (en) | 1994-09-27 | 1996-04-04 | Virotex Corporation | Improved topical carriers for mucosal applications |
US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5763910A (en) | 1995-01-31 | 1998-06-09 | Fujitsu Limited | Semiconductor device having a through-hole formed on diffused layer by self-alignment |
US5711936A (en) * | 1995-06-05 | 1998-01-27 | Whitehill Oral Technologies, Inc. | Ultramulsion based ingestible compositions |
US5679390A (en) | 1995-07-27 | 1997-10-21 | Conover; Donald Robert | Composition and method for making/using a natural fat-free, deep-fried flavoring |
US5863910A (en) | 1996-01-12 | 1999-01-26 | Bolonick; Joel | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
US5889028A (en) * | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
ATE400299T1 (de) | 1996-07-12 | 2008-07-15 | Daiichi Seiyaku Co | Schnell zerfallende, druckgeformte materialien sowie prozess zu deren herstellung |
US6599927B2 (en) | 1996-10-11 | 2003-07-29 | Astrazeneca Ab | Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome |
FR2756739B1 (fr) | 1996-12-05 | 2000-04-28 | Astra Ab | Nouvelle formulation de budesonide |
SE9604486D0 (sv) | 1996-12-05 | 1996-12-05 | Astra Ab | Novel formulation |
US5837713A (en) | 1997-02-26 | 1998-11-17 | Mayo Foundation For Medical Education And Research | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids |
US6495167B2 (en) | 1997-03-20 | 2002-12-17 | Schering Corporation | Preparation of powder agglomerates |
AUPO625797A0 (en) | 1997-04-17 | 1997-05-15 | Sola International Holdings Ltd | Spectacles bearing sunglass lenses |
WO1998050005A1 (en) * | 1997-05-09 | 1998-11-12 | Medlogic Global Corporation | Compositions for cosmetic applications |
AU750809B2 (en) * | 1997-09-26 | 2002-07-25 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
CN100548279C (zh) | 1997-10-09 | 2009-10-14 | 德克塞尔药物技术有限公司 | 延迟的总释放胃肠道给药系统 |
SE9704186D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
US6066292A (en) | 1997-12-19 | 2000-05-23 | Bayer Corporation | Sterilization process for pharmaceutical suspensions |
SE9704833D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New formulation |
US6598603B1 (en) * | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
WO1999036060A1 (en) | 1998-01-20 | 1999-07-22 | Applied Analytical Industries, Inc. | Oral liquid compositions |
JP2002502812A (ja) | 1998-02-09 | 2002-01-29 | ジョエル・ボロニック | 胃腸管の慢性炎症疾患の治療 |
EP1054678B1 (en) | 1998-02-11 | 2003-05-28 | RTP Pharma Corporation | Combination of steroid and polyunsaturated fatty acids for treatment of inflammatory conditions |
US20020002154A1 (en) * | 1998-02-11 | 2002-01-03 | Pol-Henri Guivarc'h | Method and composition for treatment of inflammatory conditions |
US6168805B1 (en) | 1998-05-07 | 2001-01-02 | Endo Pharmaceuticals, Inc. | Aqueous process for manufacturing paroxetine solid dispersions |
US6071523A (en) | 1998-06-03 | 2000-06-06 | Taro Pharmaceuticals Industries, Ltd. | Spill resistant pharmaceutical compositions in semi-solid form |
GB9812426D0 (en) | 1998-06-10 | 1998-08-05 | Reckitt & Colmann Prod Ltd | Improvements in or relating to organic compositions |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
GB2338896B (en) * | 1998-07-02 | 2003-05-21 | Reckitt & Colmann Prod Ltd | Chewable Capsules |
US20020009478A1 (en) | 1998-08-24 | 2002-01-24 | Douglas Joseph Dobrozsi | Oral liquid mucoadhesive compositions |
US6319513B1 (en) | 1998-08-24 | 2001-11-20 | The Procter & Gamble Company | Oral liquid mucoadhesive compounds |
US20010016577A1 (en) | 1998-08-24 | 2001-08-23 | Douglas Joseph Dobrozsi | Oral mucoadhesive compositions containing gastrointestinal actives |
US6028095A (en) | 1998-10-15 | 2000-02-22 | Warner-Lambert Company | Treatment of inflammatory bowel disease using histamine H3 -receptor agonists |
US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US6635281B2 (en) | 1998-12-23 | 2003-10-21 | Alza Corporation | Gastric retaining oral liquid dosage form |
NZ513037A (en) | 1999-01-29 | 2003-05-30 | Disphar Internat B | Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6136603A (en) | 1999-03-26 | 2000-10-24 | Isis Pharmaceuticals Inc. | Antisense modulation of interleukin-5 signal transduction |
GB9910212D0 (en) * | 1999-05-05 | 1999-06-30 | Reckitt & Colmann Prod Ltd | Improvements in or relating to organic compositions |
TWI263496B (en) * | 1999-12-10 | 2006-10-11 | Novartis Ag | Pharmaceutical combinations and their use in treating gastrointestinal disorders |
US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
US20010049366A1 (en) * | 2000-02-09 | 2001-12-06 | Alcon Universal Ltd. | Topical solution formulations containing an antibiotic and a corticosteroid |
AU2001243205A1 (en) | 2000-02-22 | 2001-09-03 | U.S. Army Institute Of Surgical Research | Syringe holder attachment for medication |
US20040115133A1 (en) | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
WO2002002081A1 (en) | 2000-07-05 | 2002-01-10 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and methods of using same |
US6375982B1 (en) | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
IT1318649B1 (it) | 2000-07-28 | 2003-08-27 | Propharma S R L Ora Sinclair P | Composizioni farmaceutiche per il trattamento di mucositi e stomatiti. |
US6387383B1 (en) * | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6488937B1 (en) | 2000-08-23 | 2002-12-03 | William Smits | Allergy treatment method using a rapid immunotherapy protocol |
AU2001290989A1 (en) | 2000-09-19 | 2002-04-02 | Humanetics Corporation | Treatment of inflammatory bowel disease by the administration of delta5-androstene-3beta-ol-7,17 dione and metabolizable precursors thereof |
CA2424770A1 (en) | 2000-10-06 | 2003-04-03 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation |
EP1331927B1 (en) | 2000-10-27 | 2007-12-12 | Leo Pharma A/S | Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid |
MXPA03004546A (es) * | 2000-11-22 | 2003-09-10 | Rxkinetix Inc | Tratamiento de mucositis. |
US20020132803A1 (en) | 2001-01-05 | 2002-09-19 | Mahendra Dedhiya | Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus |
CA2441352C (en) | 2001-02-15 | 2010-05-25 | Access Pharmaceuticals, Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
US7544348B2 (en) | 2001-02-15 | 2009-06-09 | Access Pharmaceuticals, Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
WO2002069933A1 (fr) | 2001-03-06 | 2002-09-12 | Kyowa Hakko Kogyo Co., Ltd. | Comprimés à délitement rapide dans la bouche |
IL157921A0 (en) | 2001-03-15 | 2004-03-28 | Enteron Pharmaceuticals Inc | Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids |
US20040156903A1 (en) | 2002-05-22 | 2004-08-12 | Abrams Andrew L.. | Metering and packaging of controlled release medication |
US6685971B2 (en) * | 2001-06-28 | 2004-02-03 | Rongxiang Xu | Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
FR2827517B1 (fr) * | 2001-07-23 | 2003-10-24 | Bioalliance Pharma | Systemes therapeutiques bioadhesifs a liberation prolongee |
CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
AU2002366796A1 (en) * | 2001-12-19 | 2003-07-09 | Eisai Co. Ltd | Methods using proton pump inhibitors |
US20030129242A1 (en) | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
SE0200657D0 (sv) | 2002-03-04 | 2002-03-04 | Astrazeneca Ab | Novel Formulation |
NO20024880L (no) | 2002-03-19 | 2003-09-22 | Per Hamre | Sammensetning inneholdende fosfat |
AU2003241464A1 (en) * | 2002-05-17 | 2003-12-02 | Eisai Co., Ltd. | Compositions and methods using proton pump inhibitors |
ES2199061B1 (es) | 2002-06-10 | 2005-02-16 | Laboratorios Vita, S.A. | Comprimidos bucodispersables y procedimiento para su obtencion. |
ATE541562T1 (de) | 2002-06-17 | 2012-02-15 | Taro Pharmaceuticals Usa Inc | Ibuprofen-suspension |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
US7148211B2 (en) | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
US8168170B2 (en) | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
FR2845917B1 (fr) | 2002-10-21 | 2006-07-07 | Negma Gild | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire |
EP1581234A4 (en) | 2002-11-05 | 2007-09-12 | Corcept Therapeutics Inc | METHODS FOR TREATING MIGRAINE |
SE0203410D0 (sv) | 2002-11-18 | 2002-11-18 | Astrazeneca Ab | New use |
EP1428526A1 (en) | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
US20040121003A1 (en) | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
WO2004062692A1 (en) | 2003-01-13 | 2004-07-29 | Solvay Pharmaceuticals B.V. | Formulation of poorly water-soluble active substances |
US20040208833A1 (en) | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
MXPA05008718A (es) * | 2003-02-17 | 2005-09-20 | Sun Pharmaceutical Ind Ltd | Una composicion de corticosteroide de dosis baja. |
WO2004073632A2 (en) | 2003-02-19 | 2004-09-02 | Biovail Laboratories Inc. | Rapid absorption selective 5-ht agonist formulations |
US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
CA2524268A1 (en) * | 2003-05-06 | 2004-11-18 | Altana Pharma Ag | Proton pump inhibitors for the treatment of lower abdominal disorders |
US7063862B2 (en) * | 2003-06-03 | 2006-06-20 | Biokey, Inc. | Pharmaceutical composition and method for treating |
US7758497B2 (en) | 2003-06-20 | 2010-07-20 | Contura A/S | Endoscopic attachment device |
JP2007509155A (ja) | 2003-10-21 | 2007-04-12 | アルファーマ インコーポレイテッド | クエチアピンを含有する薬剤 |
US20050095271A1 (en) | 2003-10-23 | 2005-05-05 | Crank Sports, Inc. | Electrolyte Energy Gel |
US20050175689A1 (en) | 2003-10-27 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | Coated fine particles containing drug for intrabuccally fast disintegrating tablet |
GB2408937A (en) | 2003-12-09 | 2005-06-15 | Johnson & Johnson Medical Ltd | pH dependent medicinal compositions |
US20050153946A1 (en) | 2003-12-24 | 2005-07-14 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
US20070020196A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
WO2005074930A1 (en) * | 2004-01-28 | 2005-08-18 | Altana Pharma Ag | Pharmaceutical combinations of (s) -pantoprazole with nsaid or corticosteroids |
CN102764247B (zh) | 2004-01-30 | 2016-04-20 | 考里安国际公司 | 递送活性剂的快速溶解膜 |
US7758877B2 (en) | 2004-02-05 | 2010-07-20 | Taro Pharmaceuticals U.S.A., Inc. | Stable loratadine spill resistant formulation |
JP2007532677A (ja) * | 2004-04-16 | 2007-11-15 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ |
WO2005102287A2 (en) | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
US20050238597A1 (en) | 2004-04-26 | 2005-10-27 | Mccook John P | Topical treatment of acne, seborrheic dermatitis, and oily skin with formulations containing histamine antagonists |
EP1765406A4 (en) | 2004-05-21 | 2012-11-28 | Mediplex Corp | ADDITIVES FOR IMPROVED MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS |
WO2005120517A1 (en) | 2004-06-07 | 2005-12-22 | Strides Arcolab Limited | Stable liquid suspension formulation comprising synthetic steroids and process for producing the same |
WO2006009825A1 (en) | 2004-06-17 | 2006-01-26 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
US7858115B2 (en) | 2004-06-24 | 2010-12-28 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
WO2006000583A2 (en) | 2004-06-28 | 2006-01-05 | Solvay Pharmaceuticals B.V. | Oral sustained release formulation of tedisamil with gastric retention properties |
US20060013873A1 (en) | 2004-07-16 | 2006-01-19 | Chih-Chiang Yang | Bioadhesive dosage form of steroids |
US20070292523A1 (en) | 2004-09-27 | 2007-12-20 | Joey Moodley | Dihydropyrimidine Formulations |
ITTO20040760A1 (it) | 2004-11-03 | 2005-02-03 | Uni Degli Studi Del Piemonte | Uso di un corticosteroide in associazione ad altri principi attivi per il trattamento della stenosi vascolare e la prevenzione della restenosi vascolare |
JP2006158379A (ja) | 2004-11-15 | 2006-06-22 | Kao Corp | 脂質燃焼促進用容器詰飲料 |
EP1827378A2 (en) | 2004-11-17 | 2007-09-05 | Government of The United States of America, as represented by Secretary, Department of Health and Human Services | Steroid formulation and methods of treatment using same |
WO2006056066A1 (en) | 2004-11-29 | 2006-06-01 | Tir Systems Ltd. | Integrated modular lighting unit |
US20070134280A1 (en) | 2004-12-10 | 2007-06-14 | Roman Stephen B | Thixotropic ingestible formulation to treat sore throat |
WO2006065991A2 (en) | 2004-12-17 | 2006-06-22 | Dr. Reddy's Laboratories Ltd. | Dispersion for delivering active agents |
KR20070111497A (ko) * | 2005-02-10 | 2007-11-21 | 오렉쏘 에이비 | 약의 경점막 투여에 유용한 새로운 약학 조성물 |
WO2006117803A2 (en) | 2005-03-14 | 2006-11-09 | Devarajan, Padma, Venkitachalam | Transmucosal drug delivery systems |
CN101175480A (zh) | 2005-03-16 | 2008-05-07 | 伊兰制药国际有限公司 | 纳米微粒白三烯受体拮抗剂/皮质类固醇制剂 |
CA2602341A1 (en) | 2005-03-23 | 2006-09-28 | Elan Pharma International Limited | Nanoparticulate corticosteroid and antihistamine formulations |
WO2006103702A2 (en) * | 2005-04-01 | 2006-10-05 | Mccullough Ricky W | Enhanced bio-adherent polymeric compositions for coating mucosal and epidermal epithelium |
FR2884422B1 (fr) | 2005-04-18 | 2008-04-11 | Roquette Freres | Composition anti-inflammatoire de l'intestin comprenant des maltodextrines branchees |
EP1877039A4 (en) | 2005-05-06 | 2010-08-18 | Salix Pharmaceuticals Inc | Polyethylene glycol GUT CLEANING COMPOSITION |
IL168603A (en) | 2005-05-16 | 2011-05-31 | Resdevco Res And Dev Co | Pharmaceutical or cosmetic composition for the prevention and treatment of irritation of mucous cells or skin cells |
US20070104785A1 (en) | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
US7799331B2 (en) * | 2005-08-04 | 2010-09-21 | Taro Pharmaceutical North America, Inc. | Oral suspension of prednisolone acetate |
EP1931316B2 (en) | 2005-08-15 | 2017-02-22 | Abbott Laboratories GmbH | Controlled release pharmaceutical compositions for acid labile drugs |
US20070059361A1 (en) | 2005-09-09 | 2007-03-15 | University Of Manitoba | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) * | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US20070116839A1 (en) | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith |
US20070116829A1 (en) | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | Pharmaceutical Composition with High-Potency Sweetener |
PT1795183E (pt) * | 2005-12-09 | 2009-08-21 | Teva Pharma | Dispersões aquosas e soluções de compostos difíceis de dissolver e métodos para a sua preparação |
US20070148248A1 (en) | 2005-12-22 | 2007-06-28 | Banner Pharmacaps, Inc. | Gastric reflux resistant dosage forms |
WO2007096906A2 (en) | 2006-02-27 | 2007-08-30 | Panacea Biotec Ltd. | Novel buccoadhesive compositions and process of preparation thereof |
WO2007123955A2 (en) | 2006-04-19 | 2007-11-01 | Novadel Pharma Inc. | Stable hydroalcoholic oral spray formulations and methods |
US7711383B2 (en) | 2006-06-30 | 2010-05-04 | Motorola, Inc. | Method and system for communicating within a communication network |
US20080161275A1 (en) | 2006-12-05 | 2008-07-03 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of inflammatory disease |
CN101674813A (zh) | 2007-01-22 | 2010-03-17 | 诺瓦瓦克斯股份有限公司 | 水溶性差的药物的用于减小进食/禁食差异性和改善口服生物利用度的多相药物制剂 |
US9050368B2 (en) * | 2007-11-13 | 2015-06-09 | Meritage Pharma, Inc. | Corticosteroid compositions |
US20100216754A1 (en) | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
US20090123551A1 (en) * | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Gastrointestinal delivery systems |
GB2458403B (en) | 2007-11-13 | 2010-01-13 | Meritage Pharma Inc | Stabilised corticosteroid compositions |
US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
HUE051538T2 (hu) | 2008-08-20 | 2021-03-01 | Univ California | Kortikoszteroidok a gyomor-bél traktus gyulladásos betegségeinek kezelésére |
EP2440210A4 (en) | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
CN106421797A (zh) | 2009-10-01 | 2017-02-22 | 艾戴尔医药公司 | 口服给予的皮质类固醇组合物 |
ES2894936T3 (es) | 2010-06-24 | 2022-02-16 | Viropharma Biologics Llc | Métodos de tratamiento para la inflamación del esófago |
-
2008
- 2008-11-12 GB GB0911779A patent/GB2458403B/en active Active
- 2008-11-12 PT PT172101628T patent/PT3354276T/pt unknown
- 2008-11-12 EP EP08850126.7A patent/EP2214679B1/en not_active Revoked
- 2008-11-12 EP EP08849579A patent/EP2214678A2/en not_active Withdrawn
- 2008-11-12 US US12/269,765 patent/US20090149433A1/en not_active Abandoned
- 2008-11-12 PT PT88485974T patent/PT2211896T/pt unknown
- 2008-11-12 EP EP08848917.4A patent/EP2214677B1/en not_active Revoked
- 2008-11-12 LT LTEP17210162.8T patent/LT3354276T/lt unknown
- 2008-11-12 MX MX2010005243A patent/MX349677B/es active IP Right Grant
- 2008-11-12 CA CA2705681A patent/CA2705681C/en active Active
- 2008-11-12 PT PT08850126T patent/PT2214679T/pt unknown
- 2008-11-12 EP EP17210162.8A patent/EP3354276B1/en not_active Revoked
- 2008-11-12 ES ES08848917.4T patent/ES2644496T3/es active Active
- 2008-11-12 EP EP08848597.4A patent/EP2211896B1/en not_active Revoked
- 2008-11-12 DK DK08848917.4T patent/DK2214677T3/da active
- 2008-11-12 ES ES08850126T patent/ES2729925T3/es active Active
- 2008-11-12 EP EP08850934A patent/EP2214652A2/en not_active Withdrawn
- 2008-11-12 LT LTEP08848597.4T patent/LT2211896T/lt unknown
- 2008-11-12 SI SI200831904T patent/SI2211896T1/en unknown
- 2008-11-12 KR KR1020107010579A patent/KR101245604B1/ko active IP Right Grant
- 2008-11-12 PL PL08850126T patent/PL2214679T3/pl unknown
- 2008-11-12 RU RU2010119165/15A patent/RU2491074C2/ru active
- 2008-11-12 AU AU2008321396A patent/AU2008321396A1/en not_active Abandoned
- 2008-11-12 ES ES08848597.4T patent/ES2660141T3/es active Active
- 2008-11-12 ES ES19165329T patent/ES2908290T3/es active Active
- 2008-11-12 EP EP19165329.4A patent/EP3574914B1/en not_active Revoked
- 2008-11-12 DK DK17210162.8T patent/DK3354276T3/da active
- 2008-11-12 CA CA2704946A patent/CA2704946C/en active Active
- 2008-11-12 WO PCT/US2008/012780 patent/WO2009064457A2/en active Application Filing
- 2008-11-12 JP JP2010533342A patent/JP2011503113A/ja active Pending
- 2008-11-12 HU HUE08848597A patent/HUE038452T2/hu unknown
- 2008-11-12 CA CA2704957A patent/CA2704957A1/en not_active Abandoned
- 2008-11-12 JP JP2010533129A patent/JP2011503074A/ja active Pending
- 2008-11-12 JP JP2010533128A patent/JP2011503073A/ja active Pending
- 2008-11-12 WO PCT/US2008/012783 patent/WO2009064460A2/en active Application Filing
- 2008-11-12 WO PCT/US2008/083288 patent/WO2009064819A2/en active Application Filing
- 2008-11-12 CA CA2704949A patent/CA2704949A1/en not_active Abandoned
- 2008-11-12 PL PL08848597T patent/PL2211896T3/pl unknown
- 2008-11-12 WO PCT/US2008/012712 patent/WO2009064417A2/en active Application Filing
- 2008-11-12 DK DK08850126.7T patent/DK2214679T3/da active
- 2008-11-12 PL PL17210162T patent/PL3354276T3/pl unknown
- 2008-11-12 WO PCT/US2008/012781 patent/WO2009064458A2/en active Application Filing
- 2008-11-12 AU AU2008321395A patent/AU2008321395B2/en active Active
- 2008-11-12 ES ES17210162T patent/ES2781949T3/es active Active
- 2008-11-12 NZ NZ585268A patent/NZ585268A/xx unknown
- 2008-11-12 SI SI200832117T patent/SI3354276T1/sl unknown
- 2008-11-12 AU AU2008321030A patent/AU2008321030A1/en not_active Abandoned
- 2008-11-12 PT PT88489174T patent/PT2214677T/pt unknown
- 2008-11-12 DK DK08848597.4T patent/DK2211896T3/en active
- 2008-11-12 CA CA2704943A patent/CA2704943A1/en not_active Abandoned
-
2010
- 2010-05-05 IL IL205548A patent/IL205548A0/en unknown
- 2010-05-12 IL IL205711A patent/IL205711A0/en unknown
- 2010-05-12 ZA ZA2010/03358A patent/ZA201003358B/en unknown
- 2010-05-13 IL IL205740A patent/IL205740A/en active IP Right Grant
-
2013
- 2013-11-21 JP JP2013240729A patent/JP6239951B2/ja active Active
-
2014
- 2014-09-12 US US14/485,017 patent/US10293052B2/en active Active
-
2016
- 2016-04-15 JP JP2016081874A patent/JP6718290B2/ja active Active
-
2017
- 2017-08-10 IL IL253948A patent/IL253948B/en unknown
- 2017-08-10 IL IL284824A patent/IL284824A/en unknown
-
2018
- 2018-03-08 HR HRP20180408TT patent/HRP20180408T1/hr unknown
- 2018-03-20 CY CY20181100323T patent/CY1120048T1/el unknown
- 2018-05-08 JP JP2018089743A patent/JP6744891B2/ja active Active
- 2018-12-12 HK HK18115959.7A patent/HK1256861A1/zh unknown
-
2019
- 2019-04-02 US US16/373,014 patent/US11357859B2/en active Active
-
2020
- 2020-03-26 HR HRP20200495TT patent/HRP20200495T1/hr unknown
- 2020-03-26 CY CY20201100284T patent/CY1123126T1/el unknown
-
2023
- 2023-04-06 US US18/131,424 patent/US20230255984A1/en not_active Abandoned
- 2023-12-08 US US18/533,956 patent/US20240108730A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2458403A (en) | Corticosteroid compositions | |
EP2440210A4 (en) | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES | |
EA031157B9 (ru) | Вводимая перорально кортикостероидная композиция | |
CY1123279T1 (el) | Κορτικοστεροειλη για τη θεραπεια φλεγμονωδων παθησεων της γαστρεντερικης οδου | |
WO2008120098A3 (en) | Peptide prodrugs | |
WO2011163614A3 (en) | Methods of treatment for esophageal inflammation | |
WO2008061720A3 (en) | Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders | |
UY32822A (es) | Composiciones farmacéuticas para el tratamiento de cáncer y otras enfermedades o trastornos | |
WO2010141074A3 (en) | O-glcnac transferase inhibitors and uses thereof | |
MX2010002559A (es) | Composiciones y metodos para tratar enfermedades y desordenes inmulogicos e inflamatorios. | |
MY174797A (en) | Anti-inflammatory compositions | |
CL2008002384A1 (es) | Compuestos derivados de quinoliniloxipiperidina y pirrolidina, composicion farmaceutica, combinacion farmaceutica, util para el tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio. | |
WO2011022393A3 (en) | Phosphatidylcholine transfer protein inhibitors | |
WO2008100628A3 (en) | Glutathione peroxidase mimetics for treatment of neurodegenerative, pulmonary and inflammatory diseases | |
UA94737C2 (ru) | Соединения на основе имидазола, композиция, которая их содержит, и их применение | |
MX2020007368A (es) | Composiciones estables de corticosteroides. | |
WO2011159254A3 (en) | The use of des-aspartate-angiotensin i in inflammation-related pathologies and diseases | |
MY192035A (en) | Orally administered corticosteroid compositions | |
PL2214677T3 (pl) | Kompozycje do leczenia zapalenia przewodu pokarmowego | |
WO2008120131A3 (en) | Pharmaceutical compositions of diclofenac and misoprostol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |